-
Once a crumbling relic of old Iran, brewery reborn as arts hub
-
Djokovic seeks Indian Wells resurgence with help from Murray
-
Musk's SpaceX faces new Starship setback
-
Trump signs executive order establishing 'Strategic Bitcoin Reserve'
-
Australian casino firm scrambles for cash to survive
-
NYC High Line architect Scofidio dead at 89
-
Musk's SpaceX faces setback with new Starship upper stage loss
-
Australians told 'prepare for worst' as tropical cyclone nears
-
Clark edges two clear at Arnold Palmer Invitational
-
Super cool: ATP sensation Fonseca learning to deal with demands of fame
-
Trump again casts doubt on his commitment to NATO
-
EU leaders agree defence boost as US announces new talks with Kyiv
-
48 killed in 'most violent' Syria unrest since Assad ouster: monitor
-
US and European stocks gyrate on tariffs and growth
-
Deja vu on the Moon: Private US spaceship again lands awkwardly
-
Brazilian teen Fonseca into Indian Wells second round
-
Abortion access under threat in Milei's Argentina
-
Trump backs off Mexico, Canada tariffs after market blowback
-
Trump car tariff pivot and Detroit's 'Big Three'
-
Man Utd draw in Spain in Europa League last 16 as Spurs beaten
-
California's Democratic governor says trans women in sports 'unfair'
-
Trump says Musk should use 'scalpel' not 'hatchet' in govt cuts
-
Goodall, Shatner to receive environmentalist awards from Sierra Club
-
Dingwall glad to be 'the glue' of England's back-line against Italy
-
Chelsea edge Copenhagen in Conference League last 16 first leg
-
Real Sociedad fight back to earn Man United draw in Europa League
-
Chunky canines: Study reveals dog obesity gene shared by humans
-
Europe rallies behind Zelensky as US announces new talks with Kyiv
-
Drop in US border crossings goes deeper than Trump
-
Guyana appeals to UN court as Venezuelan plans vote in disputed zone
-
Private US spaceship lands near Moon's south pole in uncertain condition
-
Saudi PIF to pay 'up to 12 months maternity leave' for tennis players
-
16 killed in 'most violent' Syria unrest since Assad ouster: monitor
-
Peru farmer confident ahead of German court battle with energy giant
-
US-Hamas talks complicate Gaza truce efforts: analysts
-
European rocket successfully carries out first commercial mission
-
SpaceX gears up for Starship launch as Musk controversy swirls
-
Trump backs off Mexico tariffs while Canada tensions simmer
-
Europe's new rocket blasts off on first commercial mission
-
SpaceX gearing up for Starship launch amid Musk controversy
-
Racked by violence, Haiti faces 'humanitarian catastrophe': MSF
-
Gisele Pelicot's daughter says has filed sex abuse case against father
-
New Zealand set for 'scrap' with India on slower pitch: Santner
-
US signals broader tariff reprieve for Canada, Mexico as trade gap grows
-
US to carry out first firing squad execution since 2010
-
Roy Ayers, godfather of neo-soul, dead at 84
-
ECB chief warns of 'risks all over' as rates cut again
-
Albania to shut down TikTok in coming days
-
Pompidou museum invites public for last look before renovation
-
Graham returns for Scotland's Six Nations match against Wales
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB